Tous Actualités
Suivre
Abonner curasan AG

curasan AG

euro adhoc: curasan AG
other
Curasan extends dental product range for US distribution
FDA grants 510(k) approval for Cerasorb® M Dental and Cerasorb® Perio

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
27.07.2005
curasan AG - specialists in regenerative medicine - today received
510(k) approval by the FDA for Cerasorb® M Dental and Cerasorb®
Perio.
Cerasorb® is a synthetic bone regeneration material that is fully
resorbed by the body and replaced with autogenous bone. Cerasorb® M
Dental is a second-generation product, featuring even faster
resorption and bone replacement. It is used in regions exposed to
lower loads and complements the classic Cerasorb®.
In addition, the company has developed a product by the name of
Cerasorb® Perio, which is designed specifically for bone defects
caused by periodontitis. Thus, curasan has taken a major step forward
in terms of developing indication-specific Cerasorb® products.
"In autumn 2004, we introduced our own sales organisation for the US
dental market. Cerasorb® M Dental and Cerasorb® Perio underline our
ambitions as a leader within the field of state-of-the-art bone
regeneration. Our target group will see the extension of our
Cerasorb® portfolio as evidence of our commitment to the marketplace
and will support our sales activities in this area," said curasan’s
CEO H.D. Rössler.
About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an
exchange-listed company, is a leading innovator within the growth
market of bone and tissue regeneration. The company has developed a
comprehensive product range centred around its synthetic bone
regeneration material Cerasorb®, for use in soft and hard tissue.
curasan AG's main goal is to occupy a leading position as a global
specialist in Regenerative Medicine. For further information, please
visit curasan’s corporate website at: www.curasan.de
end of announcement                               euro adhoc 27.07.2005 16:32:26

Further inquiry note:

Dr. Erwin Amashaufer, curasan AG, Tel. 06027/46 86 465, eMail: ir@curasan.de

Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Börsen: Frankfurter Wertpapierbörse
Berliner Wertpapierbörse
Hamburger Wertpapierbörse
Baden-Württembergische Wertpapierbörse
Börse Düsseldorf
Niedersächsische Börse zu Hannover
Bayerische Börse
Bremer Wertpapierbörse (BWB)

Plus de actualités: curasan AG
Plus de actualités: curasan AG